It is really going to come down to the fact that there will be many drugs available in the future in this and other drug class. Different physicians will prescribe and various people will take what works best for them. Diabetes has many different drugs available that compete with each other. There will be enough room in the market for Leron and other treatments.

I firmly believe that Leron with the low SAE data and great outcomes will become the leader in the drug class and pull a large percentage of the market. Time will tell...all the information and science still points to a good outcome.

I am not planning to sell anytime soon and I'll sit and watch the ups and downs until the data is released and cannot be contradicted.

IMO and good luck to all!